Vitexin
(Synonyms: 牡荆素,Apigenin 8-C-glucoside; Vitexina; 4H-1-Benzopyran-4-one, 8-β-D-glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)-) 目录号 : GN10806
Vitexin是许多传统中药的有效成分,在各种药用植物中都有发现。
Cas No.:3681-93-4
Sample solution is provided at 25 µL, 10mM.
Vitexin is an active components of many traditional Chinese medicines, and were found in various medicinal plants. Vitexin (apigenin-8-C-glucoside) has recently received increased attention due to its wide range of pharmacological effects, including but not limited to anti-oxidant, anti-cancer, anti-inflammatory, anti-hyperalgesic, and neuroprotective effects [1]. vitexin has recently received increased attention due to its wide range of pharmacological effects, including anti-cancer, anti-oxidant, anti-inflammatory, anti-nociceptive, anti-AD (AD, Alzheimer's disease), anti-hypertensive, anti-spasmodic, anti-hypoxia/ischemia injury, anti-depressant-like actions and anti-viral activities [1].
Vitexin (20 µM, 24h) significantly reduced the HIF-1α level in rat pheochromocytoma PC12 cells, not in human hepatocellular carcinoma HepG2 or in human osteosarcoma HOS cells under hypoxia [2]. Vitexin reduced the levels of VEGF (the major angiogenic factor) protein and mRNA in a dose-dependent manner [2]. 20 µM of vitexin inhibited PC12 cells invasion by approximately 66% [2]. Vitexin-induced (100 µM, 48h) apoptosis was p53 dependent in human oral cancer OC2 cells [3]. Vitexin (100 µM, 48h) induced the expression of ERK 1/2 in OC2 cells [3].
Vitexin (40 mg/kg i.g.) increased the brain weights of D-galactose-aged mice [4]. vitexin (10-40 mg/kg i.g.) increased the activity of the antioxidase system and levels of ATPase in the serum and tissue of D-galactose-aged mice [4]. Vitexin (0.3-10 mg/kg, i.p.) inhibits the mice writhing response induced by acetic acid and phenyl-p-benzoquinone (PBQ) [5]. Vitexin (1-10 mg/kg, i.p.) inhibits carrageenan-, capsaicin-, and CFA-Induced mechanical and thermal hyperalgesia [5]. Vitexin (10 mg/kg, ip, 30 min before the ipl injection of carrageenan) inhibits pro-inflammatory cytokine (TNF-α, IL-1β, IL-6, and IL-33) and enhances anti-inflammatory cytokine (IL-10) production induced by carrageenan [5].
References:
[1]. He M, Min J W, Kong W L, et al. A review on the pharmacological effects of vitexin and isovitexin[J]. Fitoterapia, 2016, 115: 74-85.
[2]. Choi H J, Eun J S, Kim B G, et al. Vitexin, an HIF-1α Inhibitor, Has Anti-metastatic Potential in PC12 Cells[J]. Molecules & Cells (Springer Science & Business Media BV), 2006, 22(3).
[3]. Yang S H, Liao P H, Pan Y F, et al. The novel p53‐dependent metastatic and apoptotic pathway induced by vitexin in human oral cancer OC2 cells[J]. Phytotherapy Research, 2013, 27(8): 1154-1161.
[4]. Dong L Y, Li S, Zhen Y L, et al. Cardioprotection of vitexin on myocardial ischemia/reperfusion injury in rat via regulating inflammatory cytokines and MAPK pathway[J]. The American Journal of Chinese Medicine, 2013, 41(06): 1251-1266.
[5]. Borghi S M, Carvalho T T, Staurengo-Ferrari L, et al. Vitexin inhibits inflammatory pain in mice by targeting TRPV1, oxidative stress, and cytokines[J]. Journal of Natural Products, 2013, 76(6): 1141-1149.
Cell experiment [1]: | |
Cell lines |
Human oral cancer cell line (OC2) |
Preparation Method |
A total of 1000 cells were seeded in a 96-well plate for 24 h before treatment with vitexin (0, 12.5, 25, 50, 100 µM). At the end of incubation, add alamarBlue reagent in an amount equal to 10% of the volume in the well. Cultures were incubated for 4 h, and then cytotoxicty was measured by using spectrophotometry at 570 and 600 nm. |
Reaction Conditions |
0, 12.5, 25, 50, 100 µM for for 48 h. |
Applications |
Increasing concentration of vitexin drastic decreased cell viability of OC2 cells. |
Animal experiment [2]: | |
Animal models |
male adult Sprague-Dawley (SD) rats |
Preparation Method |
rats were randomly divided into the following six groups with 16 rats in each group: (1) sham group, sham-operated without occludes the artery, (2) I/R group, I/R alone with normal saline (NS) treatment, (3) I/R + puerarin group, puerarin was administered intravenously at a dose of 30 mg/kg, beginning at coronary ischemia and again at reperfusion, (4) I/R + vitexin 6 mg/kg group, vitexin was administered intravenously at a dose of 6 mg/kg, beginning at coronary ischemia and again at reperfusion, (5) I/R + vitexin 3 mg/kg group, vitexin was administered intravenously at a dose of 3 mg/kg, beginning at coronary ischemia and again at reperfusion, (6) I/R + vitexin 1.5 mg/kg group, vitexin was administered intravenously at a dose of 1.5 mg/kg, beginning at coronary ischemia and again at reperfusion. |
Dosage form |
Intravenous injection, 1.5, 3, 6 mg/kg |
Applications |
The elevation of the ST segment was significantly enhanced in I/R group 30 min after ischemia, 30 and 60 min after reperfusion compared with sham group. Vitexin 6 mg/kg and puerarin have a significant inhibiting effect against the elevation of the ST segment 30 and 60 min after reperfusion compared with I/R group. |
References: [1]: Yang S H, Liao P H, Pan Y F, et al. The novel p53‐dependent metastatic and apoptotic pathway induced by vitexin in human oral cancer OC2 cells[J]. Phytotherapy Research, 2013, 27(8): 1154-1161. |
Cas No. | 3681-93-4 | SDF | |
别名 | 牡荆素,Apigenin 8-C-glucoside; Vitexina; 4H-1-Benzopyran-4-one, 8-β-D-glucopyranosyl-5,7-dihydroxy-2-(4-hydroxyphenyl)- | ||
化学名 | 5,7-dihydroxy-2-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one | ||
Canonical SMILES | C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4C(C(C(C(O4)CO)O)O)O)O | ||
分子式 | C21H20O10 | 分子量 | 432.38 |
溶解度 | DMSO:47 mg/mL (108.7 mM) | 储存条件 | Store at 4°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 2.3128 mL | 11.5639 mL | 23.1278 mL |
5 mM | 0.4626 mL | 2.3128 mL | 4.6256 mL |
10 mM | 0.2313 mL | 1.1564 mL | 2.3128 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet